.jpg)
Equities analysts forecast that Edwards Lifesciences Corp will post $3.41 earnings per share for the current year. Edwards Lifesciences Corp reported sales of $759.3 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 8%. The Gateway '17 event, to be held at Cobo Center on June 20-21 and previously reported by Crain's, is expected to attract more than 1,000 US businesses, the company said in a news release.
Edwards Lifesciences Corp has 212,495,000 shares in issue which have a share price of 111.99 giving Edwards Lifesciences Corp a market capitalisation of 23.80B United States dollars. For the next financial year, analysts anticipate that the company will post sales of $3.51 billion per share, with estimates ranging from $3.4 billion to $3.67 billion. For the quarter ending Sep-17, 18 analysts have a mean sales target of 808.47 million whilst for the year ending Dec-17, 21 analysts have a mean target of 3,258.15 million.
Shares in Edwards Lifesciences (NYSE:EW) rose today after the medical device maker topped expectations on Wall Street with its 1st quarter results. (EW) on Tuesday reported first-quarter earnings of $230.2 million. Edwards Lifesciences Corp had a return on equity of 25.00% and a net margin of 19.22%. The firm earned $883.50 million during the quarter, compared to analyst estimates of $776.51 million. The firm's quarterly revenue was up 14.4% compared to the same quarter past year.
A number of research firms have commented on EW.
Threat of United States govt shutdown ebbs as Trump relents on wall funding
The following day, however, White House officials said that keeping the wall in the fiscal year 2017 budget remains a priority. If the spending bill does not pass, the government will be forced to halt all spending until spending legislation is approved.
Edwards Lifesciences (EW) stock rocketed to a six-month high Wednesday after the medical tech player reported "particular strength" in USA heart-valve-replacement sales, following several quarters of "ups and downs". Deutsche Bank AG restated a hold rating and set a $100.00 price objective on shares of Edwards Lifesciences Corp in a research note on Sunday, February 5th. Canaccord Genuity set a $140.00 target price on Edwards Lifesciences Corp and gave the company a buy rating in a research note on Monday, November 28th.
Over the last twelve months Edwards Lifesciences Corp's stock price has increased from 108.84 to 111.99, a change of 2.89%. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. The brokerage now has a $120.00 target price on the medical research company's stock.
Having a price of $98.92, Edwards Lifesciences (NYSE:EW) traded 0.98% higher on the day. 7,305,133 shares of the company's stock were exchanged. The company has market cap of $23.13 billion. Checking some other stock price data, we can see that the recent distance from the 50 day high was noted at 3.21% and the separation from the 50 day low is presently 8.48%. The shares were sold at an average price of $81.85, for a total transaction of $1,085,167.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 13,720 shares of the business's stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $89.63, for a total transaction of $4,400,833.00. The disclosure for this sale can be found here. Insiders own 2.37% of the company's stock. Hedge funds and other institutional investors own 83.99% of the company's stock. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. TCI Wealth Advisors Inc. boosted its position in Edwards Lifesciences Corporation by 30.5% in the third quarter. Quadrant Capital Group LLC now owns 1,203 shares of the medical research company's stock worth $138,000 after buying an additional 95 shares during the period. Cornerstone Advisors Inc. boosted its stake in Edwards Lifesciences Corp by 28.9% in the third quarter. The firm acquired 11,984 shares of the medical research company's stock, valued at approximately $1,123,000. Spirit of America Management Corp NY purchased a new position in Edwards Lifesciences Corp during the third quarter worth about $121,000. Quadrant Capital Group LLC now owns 1,203 shares of the medical research company's stock worth $138,000 after buying an additional 95 shares in the last quarter. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and global trademark & copyright law.
TAVR is a method of replacing a diseased heart valve via catheter.
Comments